{"entity":{"id":"nct06690775","kind":"trial","name":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer.","aka":[],"tldr":"A phase 2 trial of Pegfilgrastim in ovarian cancer, run by TORL Biotherapeutics, LLC, now recruiting.","summary":"CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. is a phase 2 interventional study registered as NCT06690775 by TORL Biotherapeutics, LLC, with 230 participants planned, started 2024-11-20 and due to reach its primary completion in 2027-10. Interventions recorded: TORL-1-23, TORL-1-23, TORL-1-23, Pegfilgrastim (drug). Conditions listed: Epithelial Ovarian Cancer, Primary Peritoneal, Fallopian Tube Cancer, Endometrioid Ovarian Cancer. No results are recorded here; the registry entry is the source.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06690775","url":"https://clinicaltrials.gov/study/NCT06690775"}],"tags":["ctgov-ingest"],"related":[],"cancers":["ovarian"],"sections":[],"technologies":[],"targets":[],"drugs":["pegfilgrastim"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06690775","phase":"2","setting":"Catalina-2: A Phase 2 Study Evaluating the Efficacy and Safety of TORL-1-23 in Women With Advanced Platinum-Resistant Epithelial Ovarian Cancer (Including Primary Peritoneal and Fallopian Tube Cancers) Expressing Claudin 6","sponsor":"TORL Biotherapeutics, LLC","enrolled":230,"outcomes":[]},"route":"/trials/nct06690775/","neighbours":{"cancer":[{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"drug":[{"id":"pegfilgrastim","kind":"drug","name":"Pegfilgrastim","route":"/drugs/pegfilgrastim/"}]}}